证券代码：688526 证券简称：科前生物 公告编号：2025-038 武汉科前生物股份有限公司 根据《关于上市公司实施员工持股计划试点的指导意见》《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法 律法规的相关规定，现将本次员工持股计划的实施进展情况公告如下： 根据参与对象实际认购和最终缴款的审验结果，本次员工持股计 划实际参与认购的员工共计 55 人，认购资金已全部实缴到位，最终 缴纳的认购资金总额为 1,769.2584 万元，认购份额对应股份数量为 股股票。 海分公司出具的《证券过户登记确认书》，公司回购专用证券账户中 所持有的 221.1573 万股公司股票已于 2025 年 8 月 8 日非交易过户至 "武汉科前生物股份有限公司－2025 年员工持股计划"证券账户（证 券账户号码：B887331558），过户价格为 8 元/股。截至本公告披露 日，本次员工持股计划证券账户持有公司股份 221.1573 万股，占公 司当前总股本的比例为 0.4745%。 根据《武汉科前生物股份有限公司 2025 年员工持股计划》的相 关规定，本次员工持股计划的存续期为 48 个月，自本员工持股 ...

Core Viewpoint - The company plans to utilize idle raised funds for cash management, not exceeding RMB 260 million, to enhance fund efficiency while ensuring the normal operation of fundraising projects and maintaining fund safety [1][2][8] Summary by Sections Investment Purpose - The company aims to improve fund efficiency and increase shareholder returns by managing temporarily idle raised funds, ensuring it does not affect the progress of fundraising projects [5][7] Fund Source and Limit - The company will use up to RMB 260 million of idle raised funds for cash management, which can be rolled over within the specified limit [2][5] Investment Duration - The investment period is valid for 12 months from the date of the board's approval [5][6] Investment Method - The company will invest in high-security, liquid products such as structured deposits, time deposits, and large certificates of deposit, ensuring compliance with relevant regulations [5][6] Impact on Daily Operations - The cash management of idle funds will not affect the normal operation of fundraising projects and is expected to enhance overall performance and shareholder returns [7][8] Approval Process - The proposal for cash management has been approved by the board and supervisory board, complying with legal and regulatory requirements [8]

Core Viewpoint - The company plans to sign a cooperation research and development agreement with Huazhong Agricultural University, which is expected to enhance its core competitiveness in the bioproducts sector and accelerate its development in the industry [1]. Summary by Relevant Sections - **Cooperation Agreement**: The proposed agreement with Huazhong Agricultural University is seen as beneficial for improving the company's competitiveness in the bioproducts field [1]. - **Compliance and Procedures**: The transaction adheres to the company's articles of association, cooperation research and development management system, and the framework agreement with Huazhong Agricultural University, ensuring that all procedures are followed [1]. - **Related Party Transaction**: This transaction is classified as a related party transaction, with legal voting procedures and fair pricing, ensuring no harm to the company or its shareholders [1].

Summary of Key Points Core Viewpoint - The company intends to utilize idle raised funds for cash management to enhance fund efficiency and shareholder returns while ensuring that it does not affect the ongoing investment projects or the normal operations of the company [1][6]. Group 1: Fundraising and Usage - The company raised a total of RMB 1,227.45 million from its initial public offering (IPO) by issuing 105 million shares at a price of RMB 11.69 per share, with a net amount of RMB 1,141.73 million after deducting issuance costs of RMB 85.72 million [1][2]. - The total investment amount for the projects funded by the IPO is RMB 1,799.19 million, with RMB 1,747.03 million allocated from the raised funds [2]. - Due to a lower-than-expected net amount from the IPO, the company adjusted its investment projects, excluding certain projects and reallocating funds to ensure efficient use [2][3]. Group 2: Cash Management Plan - The company plans to use up to RMB 260 million of idle raised funds for cash management, ensuring that it does not impact the investment projects or the company's operations [3][5]. - The investment period for the cash management is valid for 12 months from the board's approval date, with a focus on low-risk, high-liquidity investment products [3][4]. - The income generated from cash management will be used to supplement any shortfall in the investment amounts for the projects and will be returned to the raised funds account upon maturity [4][6]. Group 3: Impact on Operations - The cash management of idle funds is expected to improve the efficiency of fund usage without affecting the normal progress of investment projects or the company's core business [4][6]. - By managing idle funds effectively, the company aims to achieve additional investment returns, thereby enhancing overall performance and providing greater returns to shareholders [4][6]. Group 4: Compliance and Approval - The cash management plan has been approved by the company's board and supervisory board, complying with relevant laws and regulations [5][6]. - The company will adhere to strict risk control measures and disclose information as required by regulatory authorities [4][6].

证券日报网讯 8月12日晚间，科前生物发布公告称，公司2025年8月12日召开第四届董事会第十三次会 议、第四届监事会第十二次会议审议通过了《关于使用闲置募集资金进行现金管理的议案》，同意公司 使用额度不超过人民币26，000万元（含本数）的闲置募集资金在确保不影响募集资金投资项目进度、 不影响公司正常生产经营及确保资金安全的情况下进行现金管理，在上述额度范围内，资金可以滚动使 用，使用期限自公司董事会审议通过之日起12个月内有效。 （文章来源：证券日报） ...

Group 1 - The company, Keqian Bio, announced the approval of two significant proposals during the 12th meeting of its fourth supervisory board, including a cooperation research and development agreement with Huazhong Agricultural University and a related party transaction [1] - The company also approved a proposal to utilize idle raised funds for cash management purposes [1]

格隆汇8月12日丨科前生物(688526.SH)公布，在确保不影响募集资金投资计划正常进行、不影响公司正 常生产经营及确保资金安全的前提下,使用不超过人民币26,000万元（含本数）的闲置募集资金进行现金 管理。该等闲置募集资金在上述额度内可在投资期限内滚动使用。 ...

证券代码：688526 证券简称：科前生物 公告编号：2025-039 武汉科前生物股份有限公司 2025 年员工持股计划第一次持有人会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、持有人会议召开情况 武汉科前生物股份有限公司（以下简称"公司"）2025 年员工 持股计划（以下简称"本次员工持股计划"或"2025 年员工持股计 划"）第一次持有人会议通知已于 2025 年 8 月 7 日以邮件、电话的 方式送达全体持有人。本次会议于 2025 年 8 月 12 日在公司会议室以 现场结合通讯的表决方式召开。本次会议由董事会秘书邹天天女士召 集和主持。本次会议出席的持有人共 55 名，代表本次员工持股计划 份额为 1,769.2584 万份，占本次员工持股计划份额总数的 100%。 根据《武汉科前生物股份有限公司 2025 年员工持股计划》（以 下简称"《员工持股计划》"）和《武汉科前生物股份有限公司 2025 年员工持股计划管理办法》（以下简称"《员工持股计划管理办法》"） 的相关规定，参与本次员工持股 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 关联交易简要内容：武汉科前生物股份有限公司（下称"科 前生物"或"公司"）经与华中农业大学（下称"华中农大"）竞争 性谈判，取得了"犬瘟热、犬副流感、犬腺病毒与犬细小病毒病四联 活疫苗-犬冠状病毒病灭活疫苗"、"猪盖塔病毒灭活疫苗"、"猪 增生性肠炎阻断 ELISA 抗体检测试剂盒"、"类 NADC30 猪繁殖与呼 吸综合征活疫苗（GX2024 株）"四个项目的合作研发，现拟与华中 农大签订联合开发协议书，公司就以上四个研发项目一共需向华中农 大支付 490 万元人民币。合作研发项目产生的技术成果及知识产权归 公司及华中农大共同所有； 本次交易构成关联交易，不构成《上市公司重大资产重组管 理办法》规定的重大资产重组； 证券代码：688526 证券简称：科前生物 公告编号：2025-041 武汉科前生物股份有限公司 关于拟与华中农大签订合作研发协议暨关联交易的 自愿性披露公告 本次关联交易实施不存在重大法律障碍； 本次关联交易已经公司第四届董事会独立董事 20 ...

格隆汇8月12日丨科前生物(688526.SH)公布，在确保不影响募集资金投资计划正常进行、不影响公司正 常生产经营及确保资金安全的前提下,使用不超过人民币26,000万元（含本数）的闲置募集资金进行现金 管理。该等闲置募集资金在上述额度内可在投资期限内滚动使用。 ...